Every day there are new posts in a Facebook group — 89.5 thousand members strong — dedicated to Dexcom G7 issues and complaints. From inaccurate CGM readings and sensor failures to frustrating ...

June 6 (Reuters) - Medical device maker Dexcom (DXCM.O), opens new tab said the use of its continuous glucose monitor, G7, led to improved blood sugar control in patients with type 2 diabetes not ...

The CONNECT trial, presented at the American Diabetes Association’s 2026 Scientific Sessions in New Orleans, found that 82% of adults with type 2 diabetes who used a Dexcom G7 improved their blood ...

AI may help smartwatches make glucose data more useful through better predictions, pattern detection, and personalized health ...

Adults in the US who want to measure their blood glucose levels using a wearable sensor will soon be able to buy one over-the-counter (OTC) for the first time. The FDA has cleared Dexcom’s Stelo as ...

FDA clears first over-the-counter glucose monitor for children The U.S. Food and Drug Administration said on Friday it has expanded the use of Dexcom's Stelo Glucose Biosensor ‌System to children with ...

Apple and Samsung may not need glucose-sensing smartwatches to compete in health AI. The next race is turning CGM data into useful advice.

Parents of young children with elevated blood sugar now have a new option that does not require a doctor’s prescription. The ...

Dexcom (Nadsaq:DXCM) today announced the launch of its fully reimagined Stelo over-the-counter (OTC) sensor app experience.

One of the exciting features of this tool is the option to set a user’s access time in Windows. This is useful when you do not want to depend on Microsoft Family and need something that works offline.

Terms apply to American Express benefits and offers. Visit americanexpress.com to learn more. Having a good credit score is essential to passing many of the financial milestones of life: it can help ...

A man wears the Dexcom G7 on his arm while taking photographs. [Image courtesy of Dexcom] Dexcom (Nasdaq:DXCM) today announced findings from a study demonstrating the benefits of its G7 CGM in type 2 ...